163 related articles for article (PubMed ID: 32472235)
1. A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
Kim MS; Hong HK; Ko YJ; Park KH; Ueno S; Okado S; Woo SJ; Joo K
Doc Ophthalmol; 2020 Dec; 141(3):313-318. PubMed ID: 32472235
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.
Dalal MD; Morgans CW; Duvoisin RM; Gamboa EA; Jeffrey BG; Garg SJ; Chan CC; Sen HN
Ophthalmology; 2013 Dec; 120(12):2560-2564. PubMed ID: 24053997
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.
Hung WC; Cheng HC; Wang AG
Doc Ophthalmol; 2022 Dec; 145(3):263-270. PubMed ID: 36173494
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.
Morita Y; Kimura K; Fujitsu Y; Enomoto A; Ueno S; Kondo M; Sonoda KH
Jpn J Ophthalmol; 2014 Mar; 58(2):166-71. PubMed ID: 24468869
[TBL] [Abstract][Full Text] [Related]
5. CLINICAL COURSE OF PARANEOPLASTIC RETINOPATHY WITH ANTI-TRPM1 AUTOANTIBODY IN JAPANESE COHORT.
Ueno S; Inooka D; Nakanishi A; Okado S; Yasuda S; Kominami T; Sayo A; Morimoto T; Kondo M; Katagiri S; Hayashi T; Terasaki H
Retina; 2019 Dec; 39(12):2410-2418. PubMed ID: 30260920
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.
Varin J; Reynolds MM; Bouzidi N; Tick S; Wohlschlegel J; Becquart O; Michiels C; Dereure O; Duvoisin RM; Morgans CW; Sahel JA; Samaran Q; Guillot B; Pulido JS; Audo I; Zeitz C
PLoS One; 2020; 15(4):e0231750. PubMed ID: 32324760
[TBL] [Abstract][Full Text] [Related]
7. Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice.
Xiong WH; Duvoisin RM; Adamus G; Jeffrey BG; Gellman C; Morgans CW
PLoS One; 2013; 8(8):e69506. PubMed ID: 23936334
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3.
Duvoisin RM; Haley TL; Ren G; Strycharska-Orczyk I; Bonaparte JP; Morgans CW
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2732-2738. PubMed ID: 28549093
[TBL] [Abstract][Full Text] [Related]
9. TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.
Duvoisin RM; Ren G; Haley TL; Taylor MH; Morgans CW
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2330-2335. PubMed ID: 31117125
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature.
Aronow ME; Adamus G; Abu-Asab M; Wang Y; Chan CC; Zakov ZN; Singh AD
Surv Ophthalmol; 2012 Nov; 57(6):558-64. PubMed ID: 22784677
[TBL] [Abstract][Full Text] [Related]
11. Broad locations of antigenic regions for anti-TRPM1 autoantibodies in paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
Gyoten D; Ueno S; Okado S; Chaya T; Yasuda S; Morimoto T; Kondo M; Kimura K; Hayashi T; Leroy BP; Woo SJ; Mukai R; Joo K; Furukawa T
Exp Eye Res; 2021 Nov; 212():108770. PubMed ID: 34562437
[TBL] [Abstract][Full Text] [Related]
12. Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction.
Kondo M; Sanuki R; Ueno S; Nishizawa Y; Hashimoto N; Ohguro H; Yamamoto S; Machida S; Terasaki H; Adamus G; Furukawa T
PLoS One; 2011; 6(5):e19911. PubMed ID: 21611200
[TBL] [Abstract][Full Text] [Related]
13. Clinical Findings of Melanoma-Associated Retinopathy with anti-TRPM1 Antibody.
Shinohara Y; Mukai R; Ueno S; Akiyama H
Case Rep Ophthalmol Med; 2021; 2021():6607441. PubMed ID: 34540301
[TBL] [Abstract][Full Text] [Related]
14. Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss.
Carboni G; Forma G; Bond AD; Adamus G; Iannaccone A
Doc Ophthalmol; 2012 Aug; 125(1):63-70. PubMed ID: 22569848
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication.
Lu Y; Jia L; He S; Hurley MC; Leys MJ; Jayasundera T; Heckenlively JR
Arch Ophthalmol; 2009 Dec; 127(12):1572-80. PubMed ID: 20008709
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells.
Dhingra A; Fina ME; Neinstein A; Ramsey DJ; Xu Y; Fishman GA; Alexander KR; Qian H; Peachey NS; Gregg RG; Vardi N
J Neurosci; 2011 Mar; 31(11):3962-7. PubMed ID: 21411639
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy.
Wang Y; Abu-Asab MS; Li W; Aronow ME; Singh AD; Chan CC
BMC Ophthalmol; 2012 Nov; 12():56. PubMed ID: 23148706
[TBL] [Abstract][Full Text] [Related]
19. Recoverin-associated retinopathy secondary to Warthin tumor of parotid gland.
Machida S; Ohguro H; Ishida K; Suzuki M; Kawagishi K
Doc Ophthalmol; 2014 Oct; 129(2):123-8. PubMed ID: 25149652
[TBL] [Abstract][Full Text] [Related]
20. Choroidal atrophy in a patient with paraneoplastic retinopathy and anti-TRPM1 antibody.
Ueno S; Ito Y; Maruko R; Kondo M; Terasaki H
Clin Ophthalmol; 2014; 8():369-73. PubMed ID: 24523577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
